Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
BTMD vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
BTMD vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology |
| Market Cap | $92M | $1712.35T |
| Revenue (TTM) | $188M | $0.00 |
| Net Income (TTM) | $16M | $-168M |
| Gross Margin | 70.1% | — |
| Operating Margin | 15.4% | — |
| Forward P/E | 2.8x | — |
| Total Debt | $110M | $22M |
| Cash & Equiv. | $24M | $194M |
BTMD vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| biote Corp. (BTMD) | 100 | 20.8 | -79.2% |
| DBV Technologies S.… (DBVT) | 100 | 30.6 | -69.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BTMD vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BTMD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.73, yield 2.3%
- Rev growth -2.5%, EPS growth 7.0%, 3Y rev CAGR 5.2%
- -79.2% 10Y total return vs DBVT's -87.0%
DBVT is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
- Beta 1.26 vs BTMD's 1.73
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -2.5% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 8.3% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 1.26 vs BTMD's 1.73 | |
| Dividends | 2.3% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | +110.4% vs BTMD's -37.4% | |
| Efficiency (ROA) | 15.1% ROA vs DBVT's -89.0% |
BTMD vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BTMD vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BTMD and DBVT operate at a comparable scale, with $188M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $188M | $0 |
| EBITDAEarnings before interest/tax | $32M | -$112M |
| Net IncomeAfter-tax profit | $16M | -$168M |
| Free Cash FlowCash after capex | $29M | -$151M |
| Gross MarginGross profit ÷ Revenue | +70.1% | — |
| Operating MarginEBIT ÷ Revenue | +15.4% | — |
| Net MarginNet income ÷ Revenue | +8.3% | — |
| FCF MarginFCF ÷ Revenue | +15.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -8.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -83.8% | +91.5% |
Valuation Metrics
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $92M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $178M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | 2.82x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 4.54x | — |
| Price / SalesMarket cap ÷ Revenue | 0.48x | — |
| Price / BookPrice ÷ Book value/share | — | 0.66x |
| Price / FCFMarket cap ÷ FCF | 3.05x | — |
Profitability & Efficiency
BTMD leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), BTMD scores 6/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | -130.2% |
| ROA (TTM)Return on assets | +15.1% | -89.0% |
| ROICReturn on invested capital | +11.3% | — |
| ROCEReturn on capital employed | +53.3% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | $86M | -$172M |
| Cash & Equiv.Liquid assets | $24M | $194M |
| Total DebtShort + long-term debt | $110M | $22M |
| Interest CoverageEBIT ÷ Interest expense | 3.02x | -189.82x |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $2,090 for BTMD. Over the past 12 months, DBVT leads with a +110.4% total return vs BTMD's -37.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs BTMD's -32.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -15.4% | +4.9% |
| 1-Year ReturnPast 12 months | -37.4% | +110.4% |
| 3-Year ReturnCumulative with dividends | -69.7% | +19.7% |
| 5-Year ReturnCumulative with dividends | -79.1% | -69.1% |
| 10-Year ReturnCumulative with dividends | -79.2% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -32.8% | +6.2% |
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than BTMD's 1.73 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs BTMD's 44.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.73x | 1.26x |
| 52-Week HighHighest price in past year | $4.75 | $26.18 |
| 52-Week LowLowest price in past year | $1.27 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +44.0% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 62.2 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 265K | 252K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
BTMD is the only dividend payer here at 2.25% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | +2.3% | — |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | $0.05 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +3.7% | 0.0% |
DBVT leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). BTMD leads in 1 (Profitability & Efficiency).
BTMD vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BTMD or DBVT a better buy right now?
biote Corp.
(BTMD) offers the better valuation at 2. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BTMD or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -79. 1% for biote Corp. (BTMD). Over 10 years, the gap is even starker: BTMD returned -79. 2% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BTMD or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus biote Corp. 's 1. 73β — meaning BTMD is approximately 38% more volatile than DBVT relative to the S&P 500.
04Which is growing faster — BTMD or DBVT?
On earnings-per-share growth, the picture is similar: biote Corp.
grew EPS 703. 5% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BTMD or DBVT?
biote Corp.
(BTMD) is the more profitable company, earning 14. 1% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 14. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTMD leads at 18. 5% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — BTMD leads at 71. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BTMD or DBVT?
In this comparison, BTMD (2.
3% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.
07Is BTMD or DBVT better for a retirement portfolio?
For long-horizon retirement investors, biote Corp.
(BTMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (2. 3% yield). Both have compounded well over 10 years (BTMD: -79. 2%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BTMD and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BTMD is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock. BTMD pays a dividend while DBVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.